Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Endocrine and neuroendocrine tumours

2156 - Comprehensive Genomic Profiling of Metastatic and Relapsed Thyroid Gland Carcinomas is Associated with Tumor Type and Reveals New Routes to Targeted Therapies

Date

11 Sep 2017

Session

Endocrine and neuroendocrine tumours

Presenters

Jeffrey Ross

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

J.S. Ross1, L.M. Gay2, P. Vanden Borre2, N. Almog2, A.B. Schrock3, J. Vergilio4, J. Suh4, S. Ramkissoon4, E. Severson4, S. Daniel4, S.M. Ali4, V.A. Miller4, P.J. Stephens4, J.A. Elvin4, D. Bowles5

Author affiliations

  • 1 Pathology, Albany Medical Center, 12208 - Albany/US
  • 2 Pathology, Foundation Medicine, 02141 - Cambridge/US
  • 3 Clinical Development, Foundation Medicine, MA 02141 - Cambridge/US
  • 4 R & D, Foundation Medicine, 02141 - Cambridge/US
  • 5 Medical Oncology, University of Colorado Denver, 80045 - South Aurora/US
More

Resources

Abstract 2156

Background

We queried whether CGP could differentiate the mTC subtypes of papillary (PTC), follicular (FTC), medullary (MTC) and anaplastic (ATC) carcinomas and their potential responses to targeted and immunotherapies.

Methods

CGP was performed on FFPE samples using hybridization-captured, adaptor ligation based libraries to a mean coverage depth of > 500X for up to 315 cancer-related genes. Total mutational burden (TMB) was determined on 1.1 megabases of sequenced DNA as previously described (PMID: 28420421).

Results

778 clinically advanced mTC were studied. Median age across the subtypes was similar with male patients slightly more frequent than females except for PTC. ATC had the highest median GA/sample at 4.34. BRAF was a target option for 73% of PTC and 39% of ATC, and RET for MTC in 81% of cases. Oncogenic rearrangements of RET, BRAF, ALK, and NTRK1 were detected in 8%, 3%, 1%, and 1% of PTC cases, respectively, and in 1%, 1%, 0%, and 1% of ATC cases, respectively, but not detected in any cases of FTC or MTC. At 66%, TP53 GA were most frequent in ATC. TERT GA were 58-67% in PTC, FTC and ATC and 0% in MTC. TMB was extremely low for all 4 mTC tumor types with only 3 mTC (

Conclusions

Refractory mTC patients are generally older than patients with classic localized primary PTC, and feature relatively more males. Advanced stage PTC, and to a lesser extent ATC, is frequently driven by BRAF GA or oncogenic rearrangements. Relapsed MTC is nearly universally driven by RET GA, whereas FTC has no dominant driver GA identified. TMB appears to be low for all subtypes of MTC, suggesting low potential for immunotherapies.

Clinical trial identification

Legal entity responsible for the study

Jeffrey S. Ross

Funding

None

Disclosure

J.S. Ross: Employee, leader and stock owner in Foundation Medicine. L.M. Gay, P. Vanden Borre, N. Almog, A.B. Schrock, J-A. Vergilio, J. Suh, S. Ramkissoon, E. Severson, S. Daniel, S.M. Ali, J.A. Elvin: Employee and stock owner in Foundation Medicine. V.A. Miller, P.J. Stephens: Employee, leader stock ower in Foundation Medicine. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.